{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T19:27:49Z","timestamp":1783452469699,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008967","name":"Philipps-Universit\u00e4t Marburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008967","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HNO"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Monoklonale Antik\u00f6rper (sog. Biologika) k\u00f6nnen bei chronischer Rhinosinusitis mit Nasenpolypen (CRScNP, im englischen Sprachgebrauch CRSwNP) im Rahmen ihrer Zulassung verordnet werden. Allerdings ist die Verordnung auf die schwere CRScNP ohne Krankheitskontrolle begrenzt, wobei bestimmte Voraussetzungen zu beachten sind. Derzeit sind Dupilumab, Omalizumab und Mepolizumab zugelassen, in der Literatur gibt es entsprechende Evidenz f\u00fcr ihre Wirksamkeit und Sicherheit. Es ist davon auszugehen, dass zuk\u00fcnftig weitere Biologika in dieser Indikation zugelassen werden. Die Schwere der Erkrankung sollte vor Therapieeinleitung sowie die Wirksamkeit dieser Therapie nach einem angemessenen Zeitraum objektiv und subjektiv \u00fcberpr\u00fcft werden. Hierf\u00fcr kann der in diesem aktualisierten Leitlinien-Kapitel vorgeschlagene Dokumentationsbogen verwendet werden. Bei Vorliegen von relativen Kontraindikationen sollte nur nach differenzierter Abw\u00e4gung durch erfahrene \u00c4rzt*innen und als Einzelfallentscheidung ein Therapieversuch mit Biologika erfolgen. Zusammenfassend hat das vorliegende Leitlinien-Kapitel zum Ziel, angesichts der zunehmenden Evidenz zur Therapie mit diesen Substanzen bzw. der zunehmenden Zahl an Zulassungen unterschiedlicher Biologika zu einer qualitativ hochwertigen Versorgung von erwachsenen Patient*innen mit dieser Therapieform beizutragen.<\/jats:p>","DOI":"10.1007\/s00106-023-01273-2","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T19:02:46Z","timestamp":1679338966000},"page":"256-263","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Therapie der chronischen Rhinosinusitis mit Polyposis nasi (CRScNP) mit monoklonalen Antik\u00f6rpern (Biologika): S2k-Leitlinie der Deutschen Gesellschaft f\u00fcr Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie (DGHNO-KHC) und der Deutschen Gesellschaft f\u00fcr Allgemeinmedizin und Familienmedizin (DEGAM)","Treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) with monoclonal antibodies (biologics): S2k\u00a0guideline of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), and the German College of General Practitioners and Family Physicians (DEGAM)"],"prefix":"10.1007","volume":"71","author":[{"given":"Oliver","family":"Pfaar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim Georg","family":"Beule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Laudien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris A.","family":"Stuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"erweiterte Leitliniengruppe \u201aBiologika bei CRScNP\u2018","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Aletsee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludger","family":"Klimek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Milger-Kneidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Popert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wagenmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,20]]},"reference":[{"issue":"1","key":"1273_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00106-017-0401-5","volume":"66","author":"BA Stuck","year":"2018","unstructured":"Stuck\u00a0BA, Beule\u00a0A, Jobst\u00a0D et\u00a0al (2018) Leitlinie \u201eRhinosinusitis\u201c \u2013 Langfassung. HNO 66(1):38\u201374. https:\/\/doi.org\/10.1007\/s00106-017-0401-5","journal-title":"HNO"},{"issue":"3","key":"1273_CR2","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00405-019-05752-7","volume":"277","author":"NM Kaper","year":"2020","unstructured":"Kaper\u00a0NM, van der Heijden\u00a0G, Cuijpers\u00a0SH, Stokroos\u00a0RJ, Aarts\u00a0MCJ (2020) A comparison of international clinical practice guidelines on adult chronic rhinosinusitis shows considerable variability of recommendations for diagnosis and treatment. Eur Arch Otorhinolaryngol 277(3):659\u2013668. https:\/\/doi.org\/10.1007\/s00405-019-05752-7","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"Suppl S29","key":"1273_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","volume":"58","author":"WJ Fokkens","year":"2020","unstructured":"Fokkens\u00a0WJ, Lund\u00a0VJ, Hopkins\u00a0C et\u00a0al (2020) European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology 58(Suppl S29):1\u2013464. https:\/\/doi.org\/10.4193\/Rhin20.600","journal-title":"Rhinology"},{"issue":"1","key":"1273_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","volume":"147","author":"C Bachert","year":"2021","unstructured":"Bachert\u00a0C, Han\u00a0JK, Wagenmann\u00a0M et\u00a0al (2021) EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. J\u00a0Allergy Clin Immunol 147(1):29\u201336. https:\/\/doi.org\/10.1016\/j.jaci.2020.11.013","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"1273_CR5","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1055\/a-1197-0136","volume":"99","author":"L Klimek","year":"2020","unstructured":"Klimek\u00a0L, Forster-Ruhrmann\u00a0U, Becker\u00a0S et al (2020) Positionspapier: Anwendung von Biologika bei chronischer Rhinosinusitis mit Polyposis nasi (CRSwNP) im deutschen Gesundheitssystem \u2013 Empfehlungen des Arzteverbandes Deutscher Allergologen (AeDA) und der AGs Klinische Immunologie, Allergologie und Umweltmedizin und Rhinologie und Rhinochirurgie der Deutschen Gesellschaft fur HNO-Heilkunde, Kopf- und Halschirurgie (DGHNOKHC). Laryngorhinootologie 99(8):511\u2013527. https:\/\/doi.org\/10.1055\/a-1197-0136","journal-title":"Laryngorhinootologie"},{"issue":"3","key":"1273_CR6","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jaci.2020.01.020","volume":"145","author":"C Bachert","year":"2020","unstructured":"Bachert\u00a0C, Zhang\u00a0N, Cavaliere\u00a0C, Weiping\u00a0W, Gevaert\u00a0E, Krysko\u00a0O (2020) Biologics for chronic rhinosinusitis with nasal polyps. J\u00a0Allergy Clin Immunol 145(3):725\u2013739. https:\/\/doi.org\/10.1016\/j.jaci.2020.01.020","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"1273_CR7","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1111\/all.14809","volume":"76","author":"I Agache","year":"2021","unstructured":"Agache\u00a0I, Song\u00a0Y, Alonso-Coello\u00a0P et al (2021) Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: a systematic review for the EAACI guidelines. Allergy 76(8):2337\u20132353. https:\/\/doi.org\/10.1111\/all.14809","journal-title":"Allergy"},{"key":"1273_CR8","unstructured":"Fach- und Gebrauchsinformation (SmPC) Dupixent. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/dupixent-epar-product-information_de.pdf. Zugegriffen: 3. Sept. 2021"},{"key":"1273_CR9","unstructured":"Nutzenbewertungsverfahren zum Wirkstoff Dupilumab (neues Anwendungsgebiet: Chronische Rhinosinusitis mit Nasenpolypen). https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/507\/#nutzenbewertung. Zugegriffen: 17. Febr. 2022"},{"issue":"5","key":"1273_CR10","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jama.2015.19330","volume":"315","author":"C Bachert","year":"2016","unstructured":"Bachert\u00a0C, Mannent\u00a0L, Naclerio\u00a0RM et\u00a0al (2016) Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA 315(5):469\u2013479. https:\/\/doi.org\/10.1001\/jama.2015.19330","journal-title":"JAMA"},{"issue":"10209","key":"1273_CR11","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert\u00a0C, Han\u00a0JK, Desrosiers\u00a0M et al (2019) Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 394(10209):1638\u20131650. https:\/\/doi.org\/10.1016\/S0140-6736(19)31881-1","journal-title":"Lancet"},{"issue":"1","key":"1273_CR12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/all.13984","volume":"75","author":"C Bachert","year":"2020","unstructured":"Bachert\u00a0C, Hellings\u00a0PW, Mullol\u00a0J et al (2020) Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis. Allergy 75(1):148\u2013157. https:\/\/doi.org\/10.1111\/all.13984","journal-title":"Allergy"},{"key":"1273_CR13","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin18.282","author":"C Bachert","year":"2020","unstructured":"Bachert\u00a0C, Zinreich\u00a0SJ, Hellings\u00a0PW et\u00a0al (2020) Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP. Rhinology 58(1):10\u201317. https:\/\/doi.org\/10.4193\/Rhin18.282","journal-title":"Rhinology"},{"key":"1273_CR14","unstructured":"Fach- und Gebrauchsinformation (SmPC) Xolair. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xolair-epar-product-information_de.pdf. Zugegriffen: 3. Sept. 2021"},{"issue":"3","key":"1273_CR15","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","volume":"146","author":"P Gevaert","year":"2020","unstructured":"Gevaert\u00a0P, Omachi\u00a0TA, Corren\u00a0J et\u00a0al (2020) Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J\u00a0Allergy Clin Immunol 146(3):595\u2013605. https:\/\/doi.org\/10.1016\/j.jaci.2020.05.032","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1273_CR16","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","volume":"131","author":"P Gevaert","year":"2013","unstructured":"Gevaert\u00a0P, Calus\u00a0L, Van Zele\u00a0T et\u00a0al (2013) Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J\u00a0Allergy Clin Immunol 131(1):110\u2013116e1. https:\/\/doi.org\/10.1016\/j.jaci.2012.07.047","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1273_CR17","doi-asserted-by":"publisher","first-page":"318","DOI":"10.4193\/Rhin09.144","volume":"48","author":"JM Pinto","year":"2010","unstructured":"Pinto\u00a0JM, Mehta\u00a0N, DiTineo\u00a0M, Wang\u00a0J, Baroody\u00a0FM, Naclerio\u00a0RM (2010) A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology 48(3):318\u2013324. https:\/\/doi.org\/10.4193\/Rhin09.144","journal-title":"Rhinology"},{"issue":"5","key":"1273_CR18","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/alr.21685","volume":"6","author":"RK Chandra","year":"2016","unstructured":"Chandra\u00a0RK, Clavenna\u00a0M, Samuelson\u00a0M, Tanner\u00a0SB, Turner\u00a0JH (2016) Impact of omalizumab therapy on medication requirements for chronic rhinosinusitis. Int Forum Allergy Rhinol 6(5):472\u2013477. https:\/\/doi.org\/10.1002\/alr.21685","journal-title":"Int Forum Allergy Rhinol"},{"issue":"4","key":"1273_CR19","doi-asserted-by":"publisher","first-page":"428","DOI":"10.2500\/ajr.2007.21.3060","volume":"21","author":"R Penn","year":"2007","unstructured":"Penn\u00a0R, Mikula\u00a0S (2007) The role of anti-IgE immunoglobulin therapy in nasal polyposis: a\u00a0pilot study. Research Support, Non\u2011U.S. Gov\u2019t. Am J Rhinol 21(4):428\u2013432. https:\/\/doi.org\/10.2500\/ajr.2007.21.3060","journal-title":"Am J Rhinol"},{"issue":"1","key":"1273_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4193\/Rhin17.139","volume":"56","author":"T Bidder","year":"2018","unstructured":"Bidder\u00a0T, Sahota\u00a0J, Rennie\u00a0C, Lund\u00a0VJ, Robinson\u00a0DS, Kariyawasam\u00a0HH (2018) Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together\u2014a real life study. Rhinology 56(1):42\u201345. https:\/\/doi.org\/10.4193\/Rhin17.139","journal-title":"Rhinology"},{"key":"1273_CR21","unstructured":"Fach- und Gebrauchsinformation (SmPC) Nucala. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nucala-epar-product-information_de.pdf"},{"issue":"10","key":"1273_CR22","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","volume":"9","author":"JK Han","year":"2021","unstructured":"Han\u00a0JK, Bachert\u00a0C, Fokkens\u00a0W et al (2021) Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a\u00a0randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 9(10):1141\u20131153. https:\/\/doi.org\/10.1016\/S2213-2600(21)00097-7","journal-title":"Lancet Respir Med"},{"issue":"5","key":"1273_CR23","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","volume":"128","author":"P Gevaert","year":"2011","unstructured":"Gevaert\u00a0P, Van Bruaene\u00a0N, Cattaert\u00a0T et al (2011) Mepolizumab, a\u00a0humanized anti-IL\u20115 mAb, as a\u00a0treatment option for severe nasal polyposis. J\u00a0Allergy Clin Immunol 128(5):989\u2013995 e1\u20138. https:\/\/doi.org\/10.1016\/j.jaci.2011.07.056","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1273_CR24","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","volume":"140","author":"C Bachert","year":"2017","unstructured":"Bachert\u00a0C, Sousa\u00a0AR, Lund\u00a0VJ et\u00a0al (2017) Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. Randomized controlled trial. J\u00a0Allergy Clin Immunol 140(4):1024\u20131031.e14. https:\/\/doi.org\/10.1016\/j.jaci.2017.05.044","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1273_CR25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.23822\/EurAnnACI.1764-1489.94","volume":"51","author":"M Kurosawa","year":"2019","unstructured":"Kurosawa\u00a0M, Ogawa\u00a0E, Sutoh\u00a0E (2019) Favorable clinical efficacy of mepolizumab on the upper and lower airways in severe eosinophilic asthma: a\u00a048-week pilot study. Eur Ann Allergy Clin Immunol 51(5):213\u2013221. https:\/\/doi.org\/10.23822\/EurAnnACI.1764-1489.94","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"5","key":"1273_CR26","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","volume":"118","author":"P Gevaert","year":"2006","unstructured":"Gevaert\u00a0P, Lang-Loidolt\u00a0D, Lackner\u00a0A et al (2006) Nasal IL\u20115 levels determine the response to anti-IL\u20115 treatment in patients with nasal polyps. J\u00a0Allergy Clin Immunol 118(5):1133\u20131141. https:\/\/doi.org\/10.1016\/j.jaci.2006.05.031","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"1273_CR27","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1111\/all.13875","volume":"74","author":"WJ Fokkens","year":"2019","unstructured":"Fokkens\u00a0WJ, Lund\u00a0V, Bachert\u00a0C et\u00a0al (2019) EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy 74(12):2312\u20132319. https:\/\/doi.org\/10.1111\/all.13875","journal-title":"Allergy."}],"container-title":["HNO"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-023-01273-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00106-023-01273-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-023-01273-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T13:02:44Z","timestamp":1681218164000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00106-023-01273-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,20]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1273"],"URL":"https:\/\/doi.org\/10.1007\/s00106-023-01273-2","relation":{},"ISSN":["0017-6192","1433-0458"],"issn-type":[{"value":"0017-6192","type":"print"},{"value":"1433-0458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,20]]},"assertion":[{"value":"16 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Das elektronische Zusatzumaterial wurden urspr\u00fcnglich falsch verlinkt.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die Interessenerkl\u00e4rungen als tabellarische Zusammenfassung nach dem AWMF-Regelwerk finden sich unter: .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}